carevix® Launches in Southern California and New York: Revolutionizing Pain Management in Women’s Gynecological Procedures
The launch comes at a time when updated CDC and ACOG recommendations highlight not only the importance of improved pain management for gynecological care, but also the need for clinicians to provide women with a range of alternative pain relief options.
LOS ANGELES – September 17, 2025 – After years of progress, securing FDA clearance, being named one of TIME magazine’s Best Inventions of 2024, and partnering with leading U.S. institutions such as Indiana University Health, Columbia University, and Tia Health, Aspivix, a FemTech company dedicated to modernizing gynecological care, today announced the official launch of its breakthrough device, carevix®, now available to healthcare professionals in Southern California and New York State.
This milestone delivers an innovative, less painful alternative to the century-old tenaculum for intrauterine device (IUD) placement and other transcervical procedures. It is the first step toward a nationwide rollout.
A Modern Alternative to a Century-Old Tool
carevix® is the world’s first clinically proven suction-based cervical stabilizer, designed to replace the century-old tenaculum, a sharp-toothed forceps still widely used in gynecology.
Clinical studies demonstrate that the gentle suction technology reduces pain during IUD insertions by more than 70% and bleeding by over 80% compared to the use of a traditional tenaculum. Beyond IUDs, this new suction device is designed for a broad range of gynecological and fertility procedures, including hysteroscopies, embryo transfers, intrauterine inseminations (IUI), fallopian tube patency assessments, and endometrial biopsies.
“As we launch in Los Angeles, Orange County, and New York, we are not just introducing a new device – we are in essence redefining the standard of gynecological care,”
Mathieu Horras, CEO of Aspivix.
The Right Device, at the Right Time
This launch aligns with recent CDC and ACOG recommendations that call for better pain management in gynecological procedures, particularly IUD placement. carevix® offers clinicians a timely, evidence-based alternative.
carevix® is backed by robust global clinical data and patient experience, thanks to a comprehensive real-world evidence campaign conducted across nine countries, involving 21 reference sites and more than 1,250 patients prior to launch.
This international initiative enabled Aspivix to collect valuable real-life data that demonstrates carevix®’s effectiveness and safety in diverse clinical settings, providing clinicians and patients with confidence in its use.
94% of patients reported overall satisfaction with carevix®
“My previous IUD insertion was 10/10 painful, worse than when I broke my ankle. I’d been fearful of getting a new one. But this time was so easy. I’d always choose an IUD if it’s this easy,” a patient from Tia Health said.
“The suction device was a much less painful method of stabilization than my past IUD insertion experiences,” another patient commented.
Immediate Access for Physicians, Pathway to Patients
Healthcare professionals in Los Angeles, Orange County, and New York can order carevix® directly through the new U.S. portal: myaspivix.us.
This physician-first launch provides immediate access for OB-GYNs and women’s health clinics, with patient benefits following as clinics introduce the device into routine care. Patients are encouraged to ask their providers about carevix® or visit https://www.aspivix.com/find-your-obgyn/ for a list of participating clinics
“With carevix®, we are giving women and people with a uterus access to a gentler, more respectful experience, because gynecological pain can be reduced, and it should never be dismissed as ‘just a pinch,’”
Ikram Guerd, general manager US of Aspivix.
About Aspivix
Aspivix is a pioneering FemTech company dedicated to modernizing women’s healthcare worldwide by developing innovative medical devices like carevix®, designed to transform gynecological procedures through safer and less painful solutions that enhance quality of care and empower women to take control of their health.
carevix® is Aspivix’s clinically proven cervical stabilizer, featuring soft-suction technology as a modern and gentler alternative to the traditional cervical tenaculum. In a multicenter randomized controlled trial published in Contraception (2023), carevix® significantly reduced pain and bleeding during IUD placement compared to the tenaculum.
carevix® has received FDA clearance, CE-Mark, MHRA, and ANVISA approval, and is available for commercialization in Switzerland, the U.S. (Los Angeles, Orange County, New York), UK, and Benelux. The device has also earned recognition as one of TIME magazine’s Best Inventions of 2024 and was honored with the iF Design Award 2022, underscoring its impact and innovative design.
For more information, visit www.aspivix.com
To order carevix® online, visit myaspivix.us
For media inquiries or more information :
Please contact: Ikram Guerd – VP of Global Marketing: ikram.guerd@aspivix.com.
Share this story:
More from our blog
